Biophan Technologies, Inc., a developer of next-generation medical technology, has announced that CEO Michael Weiner will present a sampling of the Company's major business and scientific achievements at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, a high-profile conference for institutional investors and other professionals active in the global biotechnology industry, scheduled for November 7-9 in the New York Palace Hotel in New York City.
Mr. Weiner will present Biophan's nanotechnology-based and other cutting-edge innovations for the medical device industry. He will also discuss revenue implications of the Company's proprietary technologies and solutions.
Among key breakthrough innovations Mr. Weiner will review are solutions that enable vascular stents, vena cava filters and other devices to be accurately imaged with Magnetic Resonance Imaging (MRI) systems. Biophan has developed nanotechnology-based and other proprietary solutions to create "visible stents" that can be imaged with MRI to provide physicians with the ability to easily and safely assess health conditions inside implanted stents, including in-stent restenosis, or to use MRI to image vena cava filters to screen for the presence of blood clots.
Mr. Weiner's presentation is scheduled for Tuesday, November 8, at 12:20 p.m., in the Adams room. Topics Mr. Weiner plans to discuss include the Company's recent progress in development of its intellectual property portfolio, its licensing and equity agreement with medical device manufacturer Boston Scientific, and the Company's recent initiative to enter the estimated $28 billion cardiovascular device marketplace.
Mr. Weiner will outline the Company's various initiatives to ensure the successful monetization of its extensive intellectual property portfolio of more than 156 US patents, licenses and applications, as well as international applications.
"We will discuss our plans to further commercialize our broad IP portfolio and other promising initiatives for high revenue growth opportunities," Mr. Weiner said. "It's extremely valuable for us to reach investment professionals active in the biomedical space, to provide additional exposure regarding our progress in developing biomedical technology innovations to improve healthcare delivery."
Biophan is developing a range of new technologies and solutions to address needs in many multibillion-dollar segments of the global biomedical industry. Among its technologies are solutions to enable medical devices to be safely and/or accurately imaged by Magnetic Resonance Imaging (MRI) systems. Such devices include pacemakers, defibrillators and neurostimulators, which currently are contraindicated for use by MRI - leaving many patients without access to a crucial diagnostic imaging option if and when they need it.
"We anticipate a shift in medical device designs that currently keep MRI out of reach for many patients, and we are proudly at the forefront of that movement," Mr. Weiner added. "Over $12 billion worth of devices are sold every year with shortcomings that make MRI inaccessible for imaging or safety reasons. We believe that these problems must be and can be solved, and we have started to see leading manufacturers such as Boston Scientific taking steps in that direction."